ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy CAMBRIDGE, Mass., Sept. 16, 2021 ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...

Sheldon Ekirch spends a lot of time on hold with her health insurance company. Sometimes, as the minutes tick by and her frustration mounts, Ekirch, 30, opens a meditation app on her phone. Patients ...

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Beyond sicca symptoms, Sjögren's disease can involve non-glandular manifestations such as dysautonomia and small fiber neuropathy that are often difficult to assess and manage. At this year's American ...

Diabetic neuropathy was the subject of a dedicated plenary session at the congress of the Francophone Diabetes Society. This already prevalent issue is becoming more prevalent and remains inadequately ...

A $3.6 million award from the National Institutes of Health will allow neurosurgical, neurology and neuroscience researchers at The Ohio State University Wexner Medical Center and College of Medicine ...